Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.

Trial Details

NCT ID
NCT06177015
Phase
PHASE3
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Darolutamide continuous
  • Darolutamide intermittent
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Patients must meet all of the following criteria to be eligible for this study:
  • Male aged ≥18 years;
  • Histologically or cytologically confirmed prostate adenocarcinoma;
  • Metastatic disease (confirmed by conventional imaging);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →